Dabrafenib mesylate

ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of dabrafenib and methanesulfonic acid. Used for treatment of metastatic melanoma.Dabrafenib Mesylate is a salt form of Dabrafenib. Dabrafenib is an inhibitor of certain mutated forms of BRAF kinase, several of which may be associated with stimulating tumour growth (e.g. the BRAF V600E mutation), and Dabrafenib is also an inhibitor of BRAF V600-mutation positive cancer cell growth, both in vitro and in vivo.

Dabrafenib mesylate is a methanesulfonate (mesylate) salt prepared from equimolar amounts of dabrafenib and methanesulfonic acid. Used for treatment of metastatic melanoma. It has a role as an antineoplastic agent and a B-Raf inhibitor. It contains a dabrafenib.|Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.

Add methylsulfonic acid (0.131 ml, 0.393 mmol) into the isopropanol solution of N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1, 1-dimethylethyl)-1, 3-thiazol-4-yl]-2-fluorophenyl}-2, 6-difluorobenzenesulfonamide (204 mg, 0.393 mmol) and stir the solution at room temperature for 3 h to obtain a white precipitate, filter the slurry and wash it with ethyl ether to obtain N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1, 1-dimethylethyl)-1, 3-thiazo-4-yl]-2-fluorophenyl]-2, 6-difluorobenzenesulfonamide methanesulfonate, which is a white crystals (221 mg, 87percent yield). Method 5: Compound B (alternative mesylate salt embodiment) - A/-{3-[5-(2-amino-4- pyrimidinyl)-2-(1 , 1 -dimethylethyl)-1 , 3-thiazol-4-yl]-2-fluorophenyl}-2, 6- difluorobenzenesulfonamide methanesulfonateA/-{3-[5-(2-amino-4-pyrimidinyl)-2-(1 , 1 -dimethylethyl)-1 , 3-thiazol-4-yl]-2-fluorophenyl}- 2, 6-difluorobenzenesulfonamide (as may be prepared according to example 58a) (2.37g, 4.56 mmol) was combined with pre-filtered acetonitrile (5.25 vol, 12.4 ml_). A pre-filtered solution of mesic acid (1 .1 eq., 5.02 mmol, 0.48 g) in HN-{3-[5-(2-amino-4-pyrimidinyl)-2-(1 , 1-dimethylethyl)-1 , 3-thiazol-4-yl]-2- fluorophenyl}-2, 6-difluorobenzenesulfonamide (as may be prepared according to example 58a) (2.37g, 4.56 mmol) was combined with pre-filtered acetonitrile (5.25 vol, 12.4 mL). A pre-filtered solution of mesic acid (1.1 eq., 5.02 mmol, 0.48 g) in HMethod 5: Compound B (alternative mesylate salt embodiment) - N-{3-[5-(2- amino-4-pyrimidinyl)-2-(l, 1 -dimethyl ethyl)-l, 3-thiazol-4-yl]-2-fluorophenyl}-2, 6- difluorobenzenesulfonamide methanesulfonate N-{3-[5-(2-amino-4-pyrimidinyl)-2-(l, l-dimethylethyl)-l, 3-thiazol-4-yl]-2- fluorophenyl}-2, 6-difluorobenzenesulfonamide (as may be prepared according to example 58a) (2.37g, 4.56 mmol) was combined with pre-filtered acetonitrile (5.25 vol, 12.4 mL). A pre-filtered solution of mesic acid (1.1 eq., 5.02 mmol, 0.48 g) in HMethod 5: Dabrafenib (alternative mesylate salt embodiment) - N-{3-[5-(2-amino-4- pyrimidinyl)-2-(l, l-dimethylethyl)-l, 3-thiazol-4-yl]-2-fluorophenyl}-2, 6- difluorobenzenesulfonamide methanesulfonate: N-{3-[5-(2-amino-4-pyrimidinyl)-2-(l, l-dimethylethyl)-l, 3-thiazol-4-yl]-2- fluorophenyl}-2, 6-difluorobenzenesulfonamide (as may be prepared according to example 58a) (2.37g, 4.56 mmol) was combined with pre-filtered acetonitrile (5.25 vol, 12.4 mL). A pre- filtered solution of mesic acid (1.1 eq., 5.02 mmol, 0.48 g) in H

Molecular Weight:615.7
Hydrogen Bond Donor Count:3
Hydrogen Bond Acceptor Count:14
Rotatable Bond Count:6
Exact Mass:615.08916689
Monoisotopic Mass:615.08916689
Topological Polar Surface Area:210
Heavy Atom Count:40
Complexity:910
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes